Resumen.-OBJETIVOS: Evaluar el impacto de los sín-tomas del tracto urinario inferior (STUI) referidos en el cuestionario IPSS sobre la calidad de vida y determinar la relación entre calidad de vida o puntuación total del IPSS con el tratamiento. MÉTODOS: Revisión retrospectiva del cuestionario IPSS de 125 hombres que habían consultado por STUI entre enero del 2001 y diciembre de 2003. La mediana de seguimiento fue de 24 meses. Los resultados fueron recogidos en una base de datos Access. Para la evaluación estadística se utilizó la versión 11.0 del SPSS. RESULTADOS: Según la puntuación del IPSS total el 17% de los pacientes presentaba síntomas severos. En la evaluación de la calidad agrupada en 2 categorías, el 88% referían buena o indiferente calidad. Al evaluar Antonio Jalón Monzón C/ Electra, 1 4ªL 33208. Gijón. Asturias. (España) ajalom@hotmail.com Summary.-OBJECTIVES: To evaluate the impact of the lower urinary tract symptoms (LUTS) included in the IPSS on the quality of life and to determine the relationship between quality of life or total IPSS score and treatment. METHODS: Retrospective review of the IPSS questionnaire in 125 male patients who had consulted for LUTS between January 2001 and December 2003. Results were included in an Access database. Statistical analyses la asociación entre los resultados del IPSS de cada pregunta y la calidad, existió asociación significativa para todas las preguntas. Los pacientes con STUI importante tenían un riesgo 6 veces mayor de mala calidad. Los pacientes que respondieron con peor calidad presentaban un riesgo 6 veces mayor de recibir tratamiento. Con un tiempo de evolución de más de 2 años de media, el 91% de los que no tenían tratamiento seguían sin él. CONCLUSIONES: Cuanto más graves sean los sínto-mas peor es la calidad de vida. Los parámetros independientes que más influyeron en la toma de decisión para iniciar un tratamiento fueron la calidad de vida y la puntuación total del IPSS. La polaquiuria, el chorro débil y la vacilación inicial pueden explicar la calidad de vida de cada paciente.

No abstract

IntroductionBacillus Calmette-Guerin (BCG) is a live attenuated strain of Mycobacterium bovis that has been used to treat urothelial carcinoma since 1976, and has been reported to eradicate disease in more than 70% of patients with in situ and stage I disease. To the best of our knowledge, we report the first case of disseminated bacillus Calmette-Guerin infection causing multiple abscesses affecting the pancreatic head and right psoas muscle, diagnosed 5 years after intravesical treatment with bacillus Calmette-Guerin therapy for bladder cancer.Case presentationAn 83-year-old Caucasian man was hospitalized with a 2-month history of back pain, anorexia, generalized weakness and a 47-pound weight loss. He had previously undergone two transurethral resections for high-grade transitional cell carcinoma of the bladder and had received 12 intravesical bacillus Calmette-Guerin instillations without any complications. He complained of abdominal pain in his right flank. A computed tomography scan of the abdomen showed multiple abscesses affecting the pancreatic head and right psoas muscle. Growth of Mycobacterium bovis was determined in cultures of the purulent material obtained by surgical drainage of the abscesses.ConclusionsThis case illustrates the fact that although intravesical administration of bacillus Calmette-Guerin is generally considered to be safe, it is not exempt from complications and these could appear immediately after treatment or as a delayed complication many years later.

Resumen.

Classically renal cell carcinoma was diagnosed when local symptoms were present (hematuria and back pain, were the most common), symptoms associated with metastasis, or the expression of a paraneoplastic syndrome. The discovery of asymptomatic renal cell carcinomas has dramatically increased, since the widespread use of ultrasound and computed tomography (CT) in the study of abdominal pathology. It is worth mentioning that, in our study, although patients diagnosed with incidental tumors had a longer time free to recurrence and survival, however, the presence of clinic was not an independent risk factor for recurrence or cancer-specific survival.